VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)
Public ClinicalTrials.gov record NCT05715125. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Patients With Active Psoriatic Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study is to evaluate if VTX958 is safe and effective in adult participants with active Psoriatic Arthritis. Approximately 195 eligible participants will take VTX958 Dose A, VTX958 Dose B, or matching placebo (no active drug) for 16 weeks and then move on to a 36 week Long Term Extension (LTE). The study will include 16 weeks of treatment, 36 weeks of LTE, and a 30-day follow-up period.
Study identification
- NCT ID
- NCT05715125
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 205 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2023 (Actual)
- Primary completion
- Jan 2, 2024 (Actual)
- Completion
- Jan 2, 2024 (Actual)
- Last update posted
- Dec 27, 2024
2023 – 2024
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site # 840001 | Phoenix | Arizona | 85032 | — |
| Site # 840016 | Newport Beach | California | 92663 | — |
| Site # 840004 | Clearwater | Florida | 33765 | — |
| Site # 840014 | Miami Lakes | Florida | 33014 | — |
| Site # 840017 | Lexington | Kentucky | 40504 | — |
| Site # 840018 | Okemos | Michigan | 48864 | — |
| Site #840012 | Saint Clair Shores | Michigan | 48081 | — |
| Site # 840019 | Eagan | Minnesota | 55121 | — |
| Site # 840003 | Middleburg Heights | Ohio | 44130 | — |
| Site # 840007 | Duncansville | Pennsylvania | 16635 | — |
| Site # 840010 | Baytown | Texas | 77521 | — |
| Site # 840006 | Lubbock | Texas | 79410 | — |
| Site # 840015 | Mesquite | Texas | 75150 | — |
| Site # 840011 | Beckley | West Virginia | 25802 | — |
| Site # 840008 | South Charleston | West Virginia | 25309 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05715125, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 27, 2024 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05715125 live on ClinicalTrials.gov.